Literature DB >> 29985739

Treatment effect on ordinal functional outcome using piecewise multistate Markov model with unobservable baseline: an application to the modified Rankin scale.

Christy Cassarly1,2, Renee' H Martin1, Marc Chimowitz3, Edsel A Peña4, Viswanathan Ramakrishnan1, Yuko Y Palesch1.   

Abstract

In clinical trials, longitudinally assessed ordinal outcomes are commonly dichotomized and only the final measure is used for primary analysis, partly for ease of clinical interpretation. Dichotomization of the ordinal scale and failure to utilize the repeated measures can reduce statistical power. Additionally, in certain emergent settings, the same measure cannot be assessed at baseline prior to treatment. For such a data set, a piecewise-constant multistate Markov model that incorporates a latent model for the unobserved baseline measure is proposed. These models can be useful in analyzing disease history data and are advantageous in clinical applications where a disease process naturally moves through increasing stages of severity. Two examples are provided using acute stroke clinical trials data. Conclusions drawn in this article are consistent with those from the primary analysis for treatment effect in both of the motivating examples. Use of these models allows for a more refined examination of treatment effect and describes the movement between health states from baseline to follow-up visits which may provide more clinical insight into the treatment effect.

Entities:  

Keywords:  Longitudinal ordinal outcome; modified Rankin Scale; panel data; piecewise multistate models

Mesh:

Year:  2018        PMID: 29985739      PMCID: PMC6326882          DOI: 10.1080/10543406.2018.1489404

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  31 in total

1.  FUNCTIONAL EVALUATION: THE BARTHEL INDEX.

Authors:  F I MAHONEY; D W BARTHEL
Journal:  Md State Med J       Date:  1965-02

2.  Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial.

Authors:  Yuko Y Palesch; Sharon D Yeatts; Thomas A Tomsick; Lydia D Foster; Andrew M Demchuk; Pooja Khatri; Michael D Hill; Edward C Jauch; Tudor G Jovin; Bernard Yan; Rüdiger von Kummer; Carlos A Molina; Mayank Goyal; Wouter J Schonewille; Mikael Mazighi; Stefan T Engelter; Craig Anderson; Judith Spilker; Janice Carrozzella; Karla J Ryckborst; L Scott Janis; Annie Simpson; Kit N Simpson; Joseph P Broderick
Journal:  Stroke       Date:  2015-04-09       Impact factor: 7.914

3.  Assessing type I error and power of multistate Markov models for panel data-A simulation study.

Authors:  Christy Cassarly; Renee' H Martin; Marc Chimowitz; Edsel A Peña; Viswanathan Ramakrishnan; Yuko Y Palesch
Journal:  Commun Stat Simul Comput       Date:  2016-09-23       Impact factor: 1.118

4.  Adopting a Patient-Centered Approach to Primary Outcome Analysis of Acute Stroke Trials Using a Utility-Weighted Modified Rankin Scale.

Authors:  Napasri Chaisinanunkul; Opeolu Adeoye; Roger J Lewis; James C Grotta; Joseph Broderick; Tudor G Jovin; Raul G Nogueira; Jordan J Elm; Todd Graves; Scott Berry; Kennedy R Lees; Andrew D Barreto; Jeffrey L Saver
Journal:  Stroke       Date:  2015-07-02       Impact factor: 7.914

5.  High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial.

Authors:  Myron D Ginsberg; Yuko Y Palesch; Michael D Hill; Renee H Martin; Claudia S Moy; William G Barsan; Bonnie D Waldman; Diego Tamariz; Karla J Ryckborst
Journal:  Lancet Neurol       Date:  2013-09-27       Impact factor: 44.182

6.  A Markov model for HIV disease progression including the effect of HIV diagnosis and treatment: application to AIDS prediction in England and Wales.

Authors:  O O Aalen; V T Farewell; D De Angelis; N E Day; O N Gill
Journal:  Stat Med       Date:  1997-10-15       Impact factor: 2.373

7.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  The ALIAS (ALbumin In Acute Stroke) Phase III randomized multicentre clinical trial: design and progress report.

Authors:  M D Ginsberg; Y Y Palesch; M D Hill
Journal:  Biochem Soc Trans       Date:  2006-12       Impact factor: 5.407

9.  Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group.

Authors:  P Lyden; T Brott; B Tilley; K M Welch; E J Mascha; S Levine; E C Haley; J Grotta; J Marler
Journal:  Stroke       Date:  1994-11       Impact factor: 7.914

10.  Percent change on the National Institutes of Health Stroke Scale: a useful acute stroke outcome measure.

Authors:  Askiel Bruno; Chandan Saha; Linda S Williams
Journal:  J Stroke Cerebrovasc Dis       Date:  2009-01       Impact factor: 2.136

View more
  1 in total

1.  Repeated Measures of Modified Rankin Scale Scores to Assess Functional Recovery From Stroke: AFFINITY Study Findings.

Authors:  Alexander Chye; Maree L Hackett; Graeme J Hankey; Erik Lundström; Osvaldo P Almeida; John Gommans; Martin Dennis; Stephen Jan; Gillian E Mead; Andrew H Ford; Christopher Etherton Beer; Leon Flicker; Candice Delcourt; Laurent Billot; Craig S Anderson; Katharina Stibrant Sunnerhagen; Qilong Yi; Severine Bompoint; Thang Huy Nguyen; Thomas Lung
Journal:  J Am Heart Assoc       Date:  2022-08-05       Impact factor: 6.106

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.